Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Zirdu who wrote (4497)	6/15/1998 9:12:00 PM
From: Bhag Karamchandani	Read Replies (1) \| Respond to of 6136

In presenting Phase I AG3304 data : what are the odds of AGPH reporting anecdotal ( individual case) account of trial participants experiencing tumor shrinkage, stablization or better still remission or retardation in the progression of tumor growth?? If the results reflect more than mere safety profiles it would be a major plus for this beleaguered stock. IMHO.

To: Zirdu who wrote (4497)	6/17/1998 7:42:00 AM
From: Henry Niman	Respond to of 6136

Here's the abstract title and authors on protease pouches and switching to Viracept: [12287] Reversal of hyperlipidaemia and lipodystrophy in patients switching therapy to nelfinavir Chris Duncombe1 M. Bloch2 D. Austin2 D. Quan2. 1Oxford Street, Darlinghurst, Sydney; 2Holdsworth Clinic, Sydney, Australia (But some have found that switching did not help: paradise-web.com